A Study of Epoetin Beta (NeoRecormon) in Participants With Solid Tumors or Hematologic Malignancies

Optimizing Treatment of the Anaemia in Onco-Hematological Diseases With NeoRecormon 30,000 IU Once Weekly

This study will evaluate the efficacy, safety, and pharmacoeconomics of treatment with subcutaneous (SC) epoetin beta (NeoRecormon) in participants with hematologic malignancies or solid tumors. The anticipated time on study treatment is 20 weeks, and the target sample size is 60 individuals.

Inclusion Criteria:

• Adults at least 18 years of age
• Multiple myeloma (MM), low-grade non-Hodgkin's lymphoma (NHL), chronic lymphocytic leukemia (CLL), breast cancer, lung cancer, or ovarian cancer
• Anemia with low erythropoeitin (EPO) levels

Exclusion Criteria:

• Poorly controlled hypertension
• Relevant acute or chronic bleeding requiring therapy within 3 months before study drug
• Treatment with EPO within the last 6 weeks
• Pregnant or breastfeeding females